A Phase 2B Study to Determine the Dose Response Pharmacokinetics of TSX-002 (Testosterone) in Hypogonadal Males
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
Price : $35 *
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors TesoRx
- 31 Aug 2018 Biomarkers information updated
- 21 Apr 2016 Primary endpoint amended and trial focus changed from PK to TU. Treatment arms changed from 2 to 6.
- 21 May 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.